Gentamicin-Sodium Citrate (gentamicin sulfate/sodium citrate)

Injection Syringe (ML); Injection Vial (ML)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Citrates (i.e., potassium citrate and citric acid, sodium citrate, sodium citrate and citric acid, tricitrates) are alkalinizing agents.

Gentamicin is an aminoglycoside antibiotic.

Generic name: gentamicin sulfate/sodium citrate
Therapeutic class: Anti-Infective Agents

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Gentamicin-Sodium Citrate

Intelligence content is not available yet.

Indications

No indications are available for this drug.

Dosing

Dosage of gentamicin sulfate is expressed in terms of gentamicin. IM and IV dosage is identical.

Like other aminoglycosides, dosage of gentamicin should be individualized taking into consideration the patient's pretreatment body weight, renal status, severity of the infection, and susceptibility of the causative organism. The manufacturers state that dosage in obese patients should be based on the patient's estimated lean body weight. Many clinicians recommend that gentamicin dosage be determined using appropriate pharmacokinetic methods for calculating dosage requirements and patient-specific pharmacokinetic parameters (e.g., elimination rate constant, volume of distribution) derived from serum concentration-time data.

Whenever possible, especially in patients with life-threatening infections, suspected toxicity or nonresponse to treatment, decreased or varying renal function, and/or when increased aminoglycoside clearance (e.g., patients with cystic fibrosis, burns) or prolonged therapy is likely, peak and trough serum concentrations of gentamicin should be determined periodically and dosage should be adjusted to maintain desired serum concentrations. (See Dosage and Administration: Dosage, in the Aminoglycosides General Statement 8:12.02.) A causal relationship between maintenance of certain peak or trough serum concentrations or other pharmacodynamic endpoints and clinical response or toxicity has not been established to date for gentamicin dosing regimens. However, for gentamicin administered in conventional dosage regimens (i.e., multiple daily doses), peak serum concentrations of 4-10 mcg/mL and trough concentrations that do not exceed 1-2 mcg/mL have been suggested. An increased risk of toxicity may be associated with peak serum gentamicin concentrations greater than 10-12 mcg/mL and/or trough concentrations greater than 2 mcg/mL. The manufacturers state that prolonged peak serum concentrations greater than 12 mcg/mL and trough concentrations greater than 2 mcg/mL should be avoided.

Parenteral aminoglycosides historically have been administered in dosage regimens that include multiple daily doses, and current prescribing information for IM or IV gentamicin only includes dosage regimens that involve multiple daily doses (usually 3 or 4 doses daily). However, there is evidence that once-daily+ (single-daily) aminoglycoside dosage regimens are at least as effective as, may provide superior pharmacokinetics, and may be less toxic than conventional dosage regimens employing multiple daily doses of the drugs. Although once-daily gentamicin regimens are recommended for some indications, once-daily gentamicin regimens should not be used in all patients and should not be used for the treatment of enterococcal or staphylococcal endocarditis+. Additional controlled studies in children, patients with renal dysfunction, and other appropriate patient groups are needed to fully define the optimal use of once-daily aminoglycoside dosing regimens. In addition, the most appropriate methods for optimizing dosage selection for once-daily regimens and monitoring serum aminoglycoside concentrations in patients receiving such regimens have not been clearly established. (See Dosage and Administration: Dosage, in the Aminoglycosides General Statement 8:12.02.)

The usual duration of gentamicin treatment is 7-10 days. In difficult and complicated infections, a longer course of treatment may be necessary. However, toxicity is more likely to occur if treatment is continued for longer than 10 days and renal, auditory, and vestibular functions should be monitored closely.

In patients with impaired renal function, doses and/or frequency of administration must be modified in response to serum concentrations of the drug and the degree of renal impairment. There are various methods to determine dosage and a wide variation in dosage recommendations for these patients. However, even when one of these methods is used, peak and trough serum concentrations of the drug should be monitored, especially in patients with changing renal function.

The manufacturers recommend that adults with renal impairment receive an initial dose of 1-1.7 mg/kg. For subsequent therapy, the manufacturers state that 1 mg/kg doses can be given at intervals (in hours) calculated by multiplying the patient's steady-state serum creatinine (in mg/dL) by 8. Alternatively, many clinicians recommend the dosing method of Sarubbi and Hull, which is based on corrected creatinine clearance. (See Dosage and Administration: Dosage in Renal Impairment, in the Aminoglycosides General Statement 8:12.02.) These dosage calculation methods should not be used in patients undergoing hemodialysis or peritoneal dialysis.

In adults with renal failure undergoing hemodialysis, the manufacturers recommend supplemental doses of 1-1.7 mg/kg at the end of each dialysis period in adults and supplemental doses of 2-2.5 mg/kg at the end of each dialysis period in children. Some clinicians suggest supplemental doses of 50-75% of the initial loading dose at the end of each dialysis period. Serum gentamicin concentrations should be monitored in dialysis patients and dosage adjusted as needed to maintain desired serum concentrations.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data